CrossRef An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection Ze-Ao Huang, Yang Yang, Shuo Yang, Guang-Shen Ji, Rui Fu, Zhi-Kang Tian, Yu-Cheng Wu, Geng-Shen Song Nature Communications .2025;[Epub] CrossRef A Study on Serum Protein Tracking in Patients with Low Levels of HBsAg Undergoing Treatment for Chronic Hepatitis B with a Combination of Tenofovir Disoproxil Fumarate and Pegylated Interferon Yimin Chen, Min Deng, Mingkai Tong, Peixia Lin, Hua Xuan, Dahai Wei Hepatitis Monthly .2025;[Epub] CrossRef Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study Jianxia Dong, Shan Ren, Jing Zhao, Pengxuan Wu, Haitian Yu, Yao Xie, Junliang Fu, Xiaorong Mao, Zhiliang Gao, Bingliang Lin, Qingfa Ruan, Yongfang Jiang, Xiulan Xue, Yueyong Zhu, Haidong Zhao, Haifang Cao, Xinyue Chen, Sujun Zheng Virology Journal .2025;[Epub] CrossRef Functional cure of chronic hepatitis B virus infection: current therapeutic regimens Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao Hepatoma Research .2025;[Epub] CrossRef 20,447 View 703 Download 25 Web of Science Crossref Viral hepatitis Abstract PDF Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with unquantifiable hepatitis B virus (HBV) DNA at 24 weeks off treatment, is a favorable treatment endpoint in chronic hepatitis B (CHB)
The glucagon receptor activation increases energy expenditure and fat oxidation, meaning your body burns more calories even at rest
Converting doses to syringe units This is where many researchers make critical errors
In 2022, the company that owns the patent of Eriomin funded a small clinical trial involving 45 people, concluding that those who took it over a 12-week period had lower blood glucose and higher GLP-1 than those who took a placebo
